Search Results

May 14, 2020

Janssen’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

Longer-term follow-up data from Phase 1b/2 CARTITUDE-1 study demonstrate 100% overall response rate, 86% stringent complete response rate at a median of 11.5 months and 86% progression-free survival at 9 months

Global health equity

April 24, 2020

Statement of Support on Access to New COVID-19 Tools

Innovative Medicine

April 24, 2020

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Submissions demonstrate Janssen’s commitment to developing new options for young patients

Global health equity

April 23, 2020

Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics

South Africa’s Rugby World Cup Winning Captain Siya Kolisi kickstarts behavior change efforts “For Humankind”; calls on other stars from sports and screen to continue to rally around protective actions, like #MaskingForAFriend

Innovative Medicine

April 22, 2020

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Patients ages 70 years or younger who were new to CLL treatment lived longer without disease progression with the IMBRUVICA®-based regimen compared to patients treated with a chemoimmunotherapy regimen

Innovative Medicine

April 3, 2020

Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal

Panel of 19 Physicians Provided Consensus Opinions on Clinical Scenarios in Which They Considered Adding Oral PPAs in Patients with PAH on ERA + PDE-5 Inhibitor Background Therapy

Innovative Medicine

March 28, 2020

Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization

XARELTO® has the potential to be the first anticoagulant in 20 years[i] to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease

Innovative Medicine

March 20, 2020

Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV

CABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression

Innovative Medicine

March 11, 2020

Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks

FLAIR Phase 3 study demonstrated patient satisfaction and preference for the long-acting injectable regimen over daily oral therapy

Innovative Medicine

March 11, 2020

Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months

ATLAS-2M Phase 3 study demonstrated patient preference over daily oral therapy for the every-two-month administration of the long-acting injectable regimen

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine